Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
bioAffinity Technologies, Inc. ( (BIAF) ) just unveiled an update.
On July 22, 2025, bioAffinity Technologies announced that it received a notification of allowance from the Canadian Patent Office for a patent application related to methods of predicting lung cancer using flow cytometry. This patent, titled ‘System and Method for Determining Lung Health,’ protects the use of specific antibodies and porphyrin TCPP to label cell populations in sputum and utilize flow cytometry to detect lung cancer cells. The patent strengthens the company’s international protection for its diagnostic platform, particularly its flagship test, CyPath® Lung. This development is significant as lung cancer is the leading cause of cancer deaths in Canada, and the patent is expected to expand bioAffinity’s market presence in the region, enhancing shareholder value and highlighting the company’s focus on early cancer detection.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
BIAF’s stock score is primarily driven by its weak financial performance, which is offset slightly by positive technical indicators and strategic corporate events. However, financial instability and regulatory challenges weigh heavily on the overall assessment.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnosis of early-stage cancer and other lung diseases, as well as broad-spectrum cancer treatments. Its first product, CyPath® Lung, is a noninvasive test marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Average Trading Volume: 7,394,760
Technical Sentiment Signal: Hold
Current Market Cap: $10.17M
Find detailed analytics on BIAF stock on TipRanks’ Stock Analysis page.